Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

The biotech could play an important role in the battle against cancer and autoimmune diseases.

Why Sorrento Therapeutics Stock Surged Today

The shares of Sorrento Therapeutics Inc (NASDAQ:SRNE) are up 6.1% to trade at $8.10 at last check, after news that the company has initiated the start of its Covid-19 test roll-out in Mexico.

Biotech Stock Surges on Covid Test Approval

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has completed the acquisition of ACEA Therapeutics Inc. (“ACEA”).

Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise

Alpha Pro Tech

Gilead Sciences

iBio

Inovio Pharmaceuticals

Novavax

QuidelOrtho Corp

The pandemic bolstered many stocks to buy. But with cases fading, this narrative is now questionable.

7 Former Pandemic Stocks to Buy That Are No Longer Running Hot

Sorrento Therapeutics Inc (NASDAQ: SRNE) reported positive initial results from the Phase 1B study of its Sofusa Lymphatic Delivery System administering Amgen Inc's (NASDAQ: AMGN) Enbrel for rheumatoid arthritis. Sofusa delivers biologic therapies through the skin directly into the lymphatic system with the potential to improve efficacy and safety and reduce the required dosing (as compared to traditional systemic or subcutaneous injections or infusions).

Sorrento Reports Encouraging Data From Sofusa-Administered Enbrel In Rheumatoid Arthritis

SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 Pivotal clinical trial of COVI-MSC™, an injectable infusion of mesenchymal stem cells, for the treatment of hospitalized COVID-19 patients suffering from ARDS.

Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the first patient has been treated in a Phase 1b proof-of-concept, open-label study to assess the safety and pilot efficacy of Enbrel administered by the Sofusa Lymphatic Delivery System for the treatment of Rheumatoid Arthritis.

Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device

Sorrento Therapeutics (SRNE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: Sorrento Therapeutics (SRNE)

The FDA has signed off  Sorrento Therapeutics Inc's (NASDAQ: SRNE) IND to proceed with a Phase 2a study for STI-3031 for advanced urothelial carcinoma. STI-3031 is based on Sorrento's G-MAB library that has fostered the development of several oncology programs currently in Phase 2 and Phase 3 clinical trials and neutralizing mAbs currently in Phase 2 trial directed against the spike protein of COVID-19 viruses.

Sorrento To Start Testing STI-3031 In Patients With Advanced Urothelial Carcinoma

SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Over the last several months, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and its development partners have advanced into clinical development (Phase 1b through Phase 3 clinical trials) a number of fully human monoclonal antibodies (mAbs) for the treatment of COVID-19 and various cancers. This demonstrates the potential of the deep pipeline generated from Sorrento's proprietary G-MAB™ library, invented by Dr. Henry Ji, the Chairman and CEO of Sorrento. This G-MAB library is based on the use of RNA transcription for amplification of the antibody variable domains from over 600 donors.  These donors were from both sexes and of multiple ethnicities, leading to a broad diversity of antibodies. In-depth analysis of deep sequencing DNA data showed that the G-MAB library contains more than 20 quadrillion (1016) distinct antibody sequences.  The G-MAB library has fostered the development of several early and late-stage oncology programs that are currently in Phase 2 and Phase 3 clinical trials and neutralizing mAbs currently in a Phase 2 clinical trial directed against the spike protein of COVID-19 viruses.

Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma

The stock price Sorrento Therapeutics Inc (NASDAQ: SRNE) increased by 10.67% today. This is why it happened.

SRNE Stock: 10.67% Increase Explanation

Hint: It's not because of anything the company said or did.

Why Sorrento Therapeutics Stock Is Soaring Today

Sorrento Therapeutics Inc (NASDAQ: SRNE) has announced data from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) infusions to treat COVID-19 induced acute respiratory failure (ARD) or acute respiratory distress syndrome (ARDS). The study met its primary objective to demonstrate the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS.

Sorrento's Human Derived Mesenchymal Stem Cells Achieves 100% Discharge Rate In Critically-Ill COVID-19 Patients

Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares lost ground Monday with no evident explanation. The stock was trending on StockTwits.

Sorrento Therapeutics Stock Looks To Form Bullish Falling Wedge

Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Sorrento will pay $38 million upfront in stock and make up to an additional $450 million in milestones payments. Beijing's BeiGene was approved to manufacture the company's approved anti-PD-1 antibody at its new Guangzhou facility.

Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between 2 San Diego-China Oncology Biopharmas

Sorrento Therapeutics recently announced the acquisition of ACEA Therapeutics. ACEA's acquisition brings to Sorrento the late clinical-stage Abivertinib.

Sorrento Therapeutics Is Still A Buy

PALO ALTO, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido® to make efficacy labeling change with clinical data.

Scilex Holding, a Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for ZTlido® Label Expansion

Vir Biotechnology

Which stock has more potential for growth over the next year? Let's look to the stars for an answer.

Vir Biotechnology vs. Sorrento Therapeutics: The Wisdom of Crowds Says.

Sorrento Therapeutics Inc (NASDAQ: SRNE) has agreed to acquire ACEA Therapeutics Inc in an all-stock deal of $38 million in shares of Sorrento common stock. Sorrento will also pay the ACEA up to $450 million in additional milestone payments and 5-10% royalty of the annual net sales.

Sorrento Therapeutics To Buy ACEA Therapeutics For $38M In Stock

Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics

Moderna

Ocugen, Inc.

VanEck Vectors Pharmaceutical ETF

AstraZeneca

Pharmaceutical stocks gained a lot from the pandemic and the race to vaccines, but most of that upside is off the table now. The post 7 Pharmaceutical Stocks That Could Get a Covid Hangover appeared first on InvestorPlace.

7 Pharmaceutical Stocks That Could Get a Covid Hangover

SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today updated positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). This ongoing study (MSC-COV-101) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for three infusions for a total of 1 x 106 cells/kg. The primary objective of this study is to evaluate the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS.

Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients

DocuSign

Peloton

Because of the pandemic, many so-called Covid stocks enjoyed outsized gains but investors might want to consider trimming their exposure. The post Take Your Profits!

Take Your Profits! 7 Covid Winners to Sell Now

Sorrento Therapeutics stock, a clinical stage biopharma company that develops treatments for cancer and neurodegenerative diseases among others, has fallen by 6% in the last week. But will the company's stock resume its downward trajectory over the coming weeks, or is a rise in the stock imminent?

Sorrento Therapeutics Stock Has Fallen 6% In A Week: Are Gains Now Expected?

SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the first patient has been treated in its Phase 1b Amyloid Light Chain (AL) Amyloidosis study of STI-6129, an ADC which uses STI-5171, a fully human monoclonal antibody (mAb) from Sorrento's G-MAB™ library. This study is being conducted as a multicenter, open-label, dose-escalation clinical trial in patients with advanced relapsed and/or refractory systemic amyloid light chain (AL) amyloidosis with a primary objective to identify a Phase 2 dose for STI-6129 based on its safety, preliminary efficacy and pharmacokinetic profile.

News for Sorrento Therapeutics Inc Stock (SRNE)